Literature DB >> 33849569

Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches.

Zahra Farzaneh1, Massoud Vosough2, Tarun Agarwal3, Maryam Farzaneh4.   

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of death due to cancer. Although there are different treatment options, these strategies are not efficient in terms of restricting the tumor cell's proliferation and metastasis. The liver tumor microenvironment contains the non-parenchymal cells with supportive or inhibitory effects on the cancerous phenotype of HCC. Several signaling pathways are dis-regulated in HCC and cause uncontrolled cell propagation, metastasis, and recurrence of liver carcinoma cells. Recent studies have established new approaches for the prevention and treatment of HCC using small molecules. Small molecules are compounds with a low molecular weight that usually inhibit the specific targets in signal transduction pathways. These components can induce cell cycle arrest, apoptosis, block metastasis, and tumor growth. Devising strategies for simultaneously targeting HCC and the non-parenchymal population of the tumor could lead to more relevant research outcomes. These strategies may open new avenues for the treatment of HCC with minimal cytotoxic effects on healthy cells. This study provides the latest findings on critical signaling pathways governing HCC behavior and using small molecules in the control of HCC both in vitro and in vivo models.

Entities:  

Keywords:  Cancer; Carcinoma; Hepatocellular carcinoma; Signaling pathways; Small molecules

Year:  2021        PMID: 33849569     DOI: 10.1186/s12935-021-01924-w

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  170 in total

Review 1.  Hepatocellular carcinoma review: current treatment, and evidence-based medicine.

Authors:  Ali Raza; Gagan K Sood
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 2.  Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.

Authors:  Wanying Li; Rui Deng; Shi Liu; Kaifeng Wang; Jian Sun
Journal:  Liver Int       Date:  2020-08-03       Impact factor: 5.828

Review 3.  Targeted therapy for hepatocellular carcinoma: Challenges and opportunities.

Authors:  Shuzhen Chen; Qiqi Cao; Wen Wen; Hongyang Wang
Journal:  Cancer Lett       Date:  2019-06-15       Impact factor: 8.679

Review 4.  Hepatocellular carcinoma: a review.

Authors:  Julius Balogh; David Victor; Emad H Asham; Sherilyn Gordon Burroughs; Maha Boktour; Ashish Saharia; Xian Li; R Mark Ghobrial; Howard P Monsour
Journal:  J Hepatocell Carcinoma       Date:  2016-10-05

Review 5.  Hepatitis B virus infection and alcohol consumption.

Authors:  Ayako Iida-Ueno; Masaru Enomoto; Akihiro Tamori; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

Review 6.  Hepatocellular carcinoma treatment: hurdles, advances and prospects.

Authors:  Ratna Kumari; Manoj Kumar Sahu; Anindita Tripathy; Kanishka Uthansingh; Manas Behera
Journal:  Hepat Oncol       Date:  2018-09-28

Review 7.  Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma.

Authors:  Chien Pong Chen
Journal:  J Clin Transl Hepatol       Date:  2019-05-27

8.  Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma.

Authors:  Yutaka Midorikawa; Tadatoshi Takayama; Hisashi Nakayama; Tokio Higaki; Masamichi Moriguchi; Kyoji Moriya; Tatsuo Kanda; Shunichi Matsuoka; Mitsuhiko Moriyama
Journal:  BMC Gastroenterol       Date:  2019-08-19       Impact factor: 3.067

Review 9.  Therapeutic Strategies in HCC: Radiation Modalities.

Authors:  R Gallicchio; A Nardelli; P Mainenti; A Nappi; D Capacchione; V Simeon; C Sirignano; F Abbruzzi; F Barbato; M Landriscina; G Storto
Journal:  Biomed Res Int       Date:  2016-08-03       Impact factor: 3.411

View more
  12 in total

Review 1.  RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?

Authors:  Kurt Sartorius; Samuel O Antwi; Anil Chuturgoon; Lewis R Roberts; Anna Kramvis
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

2.  Identification of LSM Family Members as Novel Unfavorable Biomarkers in Hepatocellular Carcinoma.

Authors:  Hongkai Zhuang; Bo Chen; Chenwei Tang; Xinming Chen; Wenliang Tan; Lei Yang; Zhiqin Xie; Xiaowu Ma; Qingbin Wang; Chuanzhao Zhang; Changzhen Shang; Yajin Chen
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

3.  Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy.

Authors:  Shiyan Yang; Yajun Cheng; Xiaolong Wang; Ping Wei; Hui Wang; Shanzhong Tan
Journal:  Front Genet       Date:  2021-11-25       Impact factor: 4.599

4.  Distinct Gene Expression Profiles in Viable Hepatocellular Carcinoma Treated With Liver-Directed Therapy.

Authors:  Kelley G Núñez; Tyler Sandow; Meredith A Lakey; Daniel Fort; Ari J Cohen; Paul T Thevenot
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

5.  Molecular and biological characterization of hepatitis B virus subgenotype F1b clusters: Unraveling its role in hepatocarcinogenesis.

Authors:  María Mercedes Elizalde; Laura Mojsiejczuk; Micaela Speroni; Belén Bouzas; Luciana Tadey; Lilia Mammana; Rodolfo Héctor Campos; Diego Martín Flichman
Journal:  Front Microbiol       Date:  2022-07-27       Impact factor: 6.064

6.  Transcriptomic Analyses Reveal Long Non-Coding RNA in Peripheral Blood Mononuclear Cells as a Novel Biomarker for Diagnosis and Prognosis of Hepatocellular Carcinoma.

Authors:  Pattapon Kunadirek; Nutcha Pinjaroen; Intawat Nookaew; Pisit Tangkijvanich; Natthaya Chuaypen
Journal:  Int J Mol Sci       Date:  2022-07-17       Impact factor: 6.208

7.  LPAL2 Suppresses Tumor Growth and Metastasis of Hepatocellular Carcinoma by Modulating MMP9 Expression.

Authors:  Yang-Hsiang Lin; Yu-Chin Liu; Cheng-Yi Chen; Hsiang-Cheng Chi; Meng-Han Wu; Po-Shuan Huang; Cheng-Chih Chang; Tzu-Kang Lin; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Cells       Date:  2022-08-22       Impact factor: 7.666

Review 8.  Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: focus on hepatocellular carcinoma.

Authors:  Veronica Zelli; Chiara Compagnoni; Roberta Capelli; Alessandra Corrente; Mauro Di Vito Nolfi; Francesca Zazzeroni; Edoardo Alesse; Alessandra Tessitore
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738

9.  Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions.

Authors:  Qiuxian Zheng; Qin Yang; Jiaming Zhou; Xinyu Gu; Haibo Zhou; Xuejun Dong; Haihong Zhu; Zhi Chen
Journal:  Cancer Cell Int       Date:  2021-06-30       Impact factor: 5.722

Review 10.  Immunotherapies for hepatocellular carcinoma.

Authors:  Justin K H Liu; Andrew F Irvine; Rebecca L Jones; Adel Samson
Journal:  Cancer Med       Date:  2021-12-24       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.